期刊
ANNUAL REVIEW OF GENETICS, VOL 49
卷 49, 期 -, 页码 47-70出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-genet-112414-054926
关键词
pluripotent stem cells; genetic correction; programmable nuclease; TALEN; CRISPR-Cas9
资金
- Grants-in-Aid for Scientific Research [15H05581] Funding Source: KAKEN
The advent of induced pluripotent stem (iPS) cells has opened up numerous avenues of opportunity for cell therapy, including the initiation in September 2014 of the first human clinical trial to treat dry age-related macular degeneration. In parallel, advances in genome-editing technologies by site-specific nucleases have dramatically improved our ability to edit endogenous genomic sequences at targeted sites of interest. In fact, clinical trials have already begun to implement this technology to control HIV infection. Genome editing in iPS cells is a powerful tool and enables researchers to investigate the intricacies of the human genome in a dish. In the near future, the groundwork laid by such an approach may expand the possibilities of gene therapy for treating congenital disorders. In this review, we summarize the exciting progress being made in the utilization of genomic editing technologies in pluripotent stem cells and discuss remaining challenges toward gene therapy applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据